The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-viral antigen-based compositions. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-viral antigen-based compositions is a key innovation area in pharmaceuticals

A viral antigen is a protein encoded by the viral genome that can be detected by a specific immunological response. Antibodies produced by the immune system attach to specific antigens and protect the body from infection by removing them.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 300+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-viral antigen-based compositions.

Key players in anti-viral antigen-based compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-viral antigen-based compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
GSK 993 Unlock Company Profile
C. H. Boehringer Sohn 718 Unlock Company Profile
Johnson & Johnson 638 Unlock Company Profile
Sanofi 583 Unlock Company Profile
Merck & Co 552 Unlock Company Profile
Takeda Pharmaceutical 446 Unlock Company Profile
Zoetis 438 Unlock Company Profile
Pfizer 367 Unlock Company Profile
Valneva 283 Unlock Company Profile
F. Hoffmann-La Roche 261 Unlock Company Profile
Regeneron Pharmaceuticals 247 Unlock Company Profile
Gilead Sciences 182 Unlock Company Profile
Inovio Pharmaceuticals 156 Unlock Company Profile
United States Of America 149 Unlock Company Profile
Mitsubishi Chemical Group 140 Unlock Company Profile
Vertex Pharmaceuticals 135 Unlock Company Profile
Vir Biotechnology 129 Unlock Company Profile
VLP Therapeutics 129 Unlock Company Profile
Centre National de la Recherche Scientifique 129 Unlock Company Profile
AstraZeneca 124 Unlock Company Profile
National Research Council of Canada 124 Unlock Company Profile
Theraclone Sciences 122 Unlock Company Profile
US Department of Health and Human Services 121 Unlock Company Profile
X4 Pharmaceuticals 120 Unlock Company Profile
Curevac 115 Unlock Company Profile
Molecular Templates 111 Unlock Company Profile
United Nations Industrial Development Organization 102 Unlock Company Profile
Bristol-Myers Squibb 96 Unlock Company Profile
Moderna 94 Unlock Company Profile
Celltrion 80 Unlock Company Profile
Trellis Bioscience 77 Unlock Company Profile
Erasmus MC 77 Unlock Company Profile
Temasek Life Sciences Laboratory 77 Unlock Company Profile
MacroGenics 72 Unlock Company Profile
Meiji Holdings 68 Unlock Company Profile
Academia Sinica 65 Unlock Company Profile
Bharat Biotech 64 Unlock Company Profile
Pomona Ricerca 61 Unlock Company Profile
Eli Lilly and 60 Unlock Company Profile
Intervet 59 Unlock Company Profile
Oswaldo Cruz Foundation 59 Unlock Company Profile
Nitto Denko 59 Unlock Company Profile
AIMM Therapeutics 59 Unlock Company Profile
Compagnie Merieux Alliance 58 Unlock Company Profile
Les Laboratoires Servier 57 Unlock Company Profile
PanTheryx 55 Unlock Company Profile
Grifols 53 Unlock Company Profile
Novavax 52 Unlock Company Profile
Solon Eiendom 50 Unlock Company Profile
Geeks On Call 49 Unlock Company Profile

Source: GlobalData Patent Analytics

GSK is one of the leading patent filers in anti-viral antigen-based compositions. GSK is a healthcare company that focuses on developing, manufacturing and commercialising pharmaceuticals, vaccines, and consumer healthcare products.. It offers drugs spanning therapeutic areas such as respiratory, oncology, immuno-inflammation, central nervous system (CNS), metabolic, cardiovascular, dermatology, bacterial infections, viral infections, including HIV, and rare diseases.  GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles, and bacterial meningitis.

In terms of application diversity, HuVet bio is the top company, followed by AbbVie and Cedars-Sinai Health System. By means of geographic reach, Providence St. Joseph Health holds the top position. While eyeGene and Fundacion IrsiCaixa are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.